Jounce Therapeutics to Present at the Jefferies 2015 Immuno-Oncology Summit
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, today announced that Richard Murray, Ph.D., chief executive officer, will present a company overview at the Jefferies 2015 Immuno-Oncology Summit today at 12 p.m. ET in Boston.
About Jounce Therapeutics
Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce integrates translational science insights to select the right targets and patient populations with higher probability of success and achieve rapid proof-of-concept. The company is advancing programs that leverage contributions from our founders as well as knowledge acquired from Jounce’s Translational Science Platform to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment, extending and improving patients’ quality of life. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.
Pure Communications, Inc.
Katie Engleman, 910-509-3977
[email protected]
Source: Jounce Therapeutics
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- Invest in Bogota ventures into Miami's thriving entrepreneurial scene for investment opportunities
- SK hynix Partners with TSMC to Strengthen HBM Technological Leadership
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!